[
    [
        {
            "time": "",
            "original_text": "中国药企巨头收入构成（附图表）",
            "features": {
                "keywords": [
                    "中国药企",
                    "收入构成",
                    "巨头"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "中国药企巨头收入构成（附图表）",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【医药】立足医改主线，精选优质个股——医药行业周报——中性（联系人：甘英健，陈晨）",
            "features": {
                "keywords": [
                    "医药",
                    "医改",
                    "优质个股",
                    "行业周报",
                    "中性"
                ],
                "sentiment_score": 0.5,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【医药】立足医改主线，精选优质个股——医药行业周报——中性（联系人：甘英健，陈晨）",
                "Correlation": 7,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【东吴医药】恒瑞深度报告：仿创结合+制剂出口奠基础，创新药龙头拔锚启航开新章",
            "features": {
                "keywords": [
                    "东吴医药",
                    "恒瑞",
                    "仿创结合",
                    "制剂出口",
                    "创新药",
                    "龙头"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【东吴医药】恒瑞深度报告：仿创结合+制剂出口奠基础，创新药龙头拔锚启航开新章",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]